Anavex Life Sciences Corp. (AVXL) Stock Price & Analysis
Anavex Life Sciences Corp. (AVXL) rose 0.35% to USD 2.86 as of September 8, 2026 at 09:02 UTC, according to Nexqual real-time market data.
AVXL last closed at USD 2.86; the session ranged USD 2.81–2.91 on volume of 307,150 shares. Market capitalization is —, with a 52-week range of USD 2.26–10.4 (NMS). Source: Nexqual, September 8, 2026 at 09:02 UTC.
Key Statistics (as of September 8, 2026 at 09:02 UTC)
| Price | USD 2.86 |
|---|---|
| Change | ▲ 0.35% (up) |
| Previous Close | USD 2.86 |
| Open | USD 2.86 |
| Day Range | USD 2.81 – 2.91 |
| 52-Week Range | USD 2.26 – 10.4 |
| Volume | 307,150 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (AVXL)
Nexqual's technical model rates AVXL "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.48 (neutral) |
| vs SMA50 | Below (USD 2.86) |
| MACD | -0.02 (negative) |
From Anavex Life Sciences Corp.'s Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX ® 2-73 (blarcamesine), our approach is to restore cellular balance (i.e. homeostasis).
- Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any products that we may develop.   17     We believe our approach to the treatment of Alzheimer's disease and other CNS diseases differs from our competitors.
- Our platform may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1.
Partnerships
- The trial will utilize standard clinical outcome measures for schizophrenia including the Positive and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led ERP Biomarker Qualification Consortium.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANVS | Annovis Bio, Inc. | USD 1.39 | ▼ 18.24% |
| FLNA | Filana Therapeutics, Inc. | USD 0.82 | ▼ 4.64% |
| AXSM | Axsome Therapeutics, Inc. | USD 206.68 | ▼ 1.54% |
| AUPH | Aurinia Pharmaceuticals Inc | USD 16.08 | ▼ 1.29% |
| VERU | Veru Inc. | USD 2.64 | ▼ 4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:02 UTC. This page is informational and not investment advice.